MDT

85.6

-1.76%↓

A

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

A

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

A

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

A

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

A

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Search

Catalyst Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

25.91 0.23

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

25.5

Max

26.01

Belangrijke statistieken

By Trading Economics

Inkomsten

-85K

53M

Verkoop

4.2M

153M

K/W

Sectorgemiddelde

15.083

63.808

EPS

0.68

Winstmarge

34.53

Werknemers

182

EBITDA

612K

81M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+33.46% upside

Dividenden

By Dow Jones

Volgende Winsten

6 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

151M

3.1B

Vorige openingsprijs

25.68

Vorige sluitingsprijs

25.91

Nieuwssentiment

By Acuity

50%

50%

162 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Catalyst Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 apr 2026, 23:26 UTC

Populaire aandelen

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16 apr 2026, 20:41 UTC

Belangrijke Marktbewegers

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16 apr 2026, 23:49 UTC

Marktinformatie

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16 apr 2026, 23:45 UTC

Marktinformatie

Nikkei May Decline After Hitting Record High -- Market Talk

16 apr 2026, 23:33 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16 apr 2026, 22:51 UTC

Marktinformatie

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16 apr 2026, 22:08 UTC

Winsten

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16 apr 2026, 22:06 UTC

Winsten

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16 apr 2026, 22:06 UTC

Winsten

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16 apr 2026, 22:06 UTC

Winsten

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16 apr 2026, 22:06 UTC

Winsten

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16 apr 2026, 22:06 UTC

Winsten

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16 apr 2026, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

16 apr 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

16 apr 2026, 20:50 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

16 apr 2026, 20:50 UTC

Marktinformatie
Winsten

Health Care Roundup: Market Talk

16 apr 2026, 20:49 UTC

Winsten

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16 apr 2026, 20:43 UTC

Winsten

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 apr 2026, 20:40 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

16 apr 2026, 20:40 UTC

Marktinformatie
Winsten

Netflix Says Engagement Quality Hits New High -- Market Talk

16 apr 2026, 20:30 UTC

Populaire aandelen

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16 apr 2026, 20:25 UTC

Winsten

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 apr 2026, 20:23 UTC

Winsten

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16 apr 2026, 20:19 UTC

Winsten

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16 apr 2026, 20:17 UTC

Winsten

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16 apr 2026, 20:17 UTC

Winsten

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16 apr 2026, 20:16 UTC

Winsten

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16 apr 2026, 20:16 UTC

Winsten

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16 apr 2026, 20:16 UTC

Winsten

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16 apr 2026, 20:16 UTC

Winsten

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Peer Vergelijking

Prijswijziging

Catalyst Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

33.46% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 34.5 USD  33.46%

Hoogste 35 USD

Laagste 33 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Catalyst Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technische score

By Trading Central

N/A / 24.28Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

162 / 348 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
help-icon Live chat